Related Experiment Videos

Prognostic factors for relapse-free survival in childhood acute lymphoblastic leukaemia

Insights

Four factors at diagnosis significantly increase relapse risk in childhood acute lymphocytic leukemia (ALL). These include high white blood cell count, high lymphoblast percentage, and specific age groups (under 2 or over 5 years).

Area of Science:

  • Pediatric Oncology
  • Hematology
  • Clinical Research

Background:

  • Childhood acute lymphocytic leukemia (ALL) is the most common childhood cancer.
  • Effective risk stratification is crucial for optimizing treatment strategies and improving outcomes.
  • Previous studies have identified various prognostic factors, but their predictive value requires ongoing validation.

Purpose of the Study:

  • To identify key prognostic variables at diagnosis that predict disease-free survival in children with acute lymphocytic leukemia.
  • To evaluate the predictive significance of 11 distinct clinical and laboratory parameters in a cohort of 267 children.

Main Methods:

  • A retrospective analysis of 267 children diagnosed with acute lymphocytic leukemia.
  • Assessment of 11 baseline variables including leucocyte count, lymphoblast percentage, age, sex, and immunological markers.
  • Statistical modeling to determine the independent prognostic value of each variable for disease-free survival.

Main Results:

  • Leucocyte count > 50 x 10(9)/l, lymphoblasts > 80% in peripheral blood, age < 2 or > 5 years, and male sex significantly increased relapse risk (risk factors 1.9, 2.3, 1.7, and 1.7, respectively).
  • Hemoglobin, platelet count, bleeding signs, extramedullary infiltrations, hepatosplenomegaly, mediastinal mass, and T- or B-cell immunophenotype did not show independent prognostic value in the presence of the four key variables.
  • Small sample sizes limited the evaluation of T- or B-cell lymphoblast type impact.

Conclusions:

  • Leukocyte count, lymphoblast percentage, age, and sex are critical prognostic indicators for childhood ALL at diagnosis.
  • These factors can guide risk stratification and potentially personalize treatment intensity.
  • Further research with larger cohorts is needed to fully elucidate the prognostic role of immunophenotype in ALL.

Related Concept Videos